Literature DB >> 2173945

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine.

N M Barnes1, J Ge, W G Jones, R J Naylor, J A Rudd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2173945      PMCID： PMC1971539          DOI： 10.1038/bjc.1990.395

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  13 in total

1.  5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.

Authors:  B Costall; A M Domeney; R J Naylor; F D Tattersall
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

2.  Serum prostaglandin F-2 alpha concentration in the carcinoid syndrome.

Authors:  J M Feldman; J W Plonk; J C Cornette
Journal:  Prostaglandins       Date:  1974-09-25

3.  First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis.

Authors:  U Leibundgut; I Lancranjan
Journal:  Lancet       Date:  1987-05-23       Impact factor: 79.321

4.  Measurement of free and bound 5-hydroxytryptophan in plasma by liquid chromatography with electrochemical detection.

Authors:  G M Tyce; E T Creagan
Journal:  Anal Biochem       Date:  1981-03-15       Impact factor: 3.365

5.  Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

Authors:  M Marty; P Pouillart; S Scholl; J P Droz; M Azab; N Brion; E Pujade-Lauraine; B Paule; D Paes; J Bons
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

6.  Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.

Authors:  W D Miner; G J Sanger
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

7.  5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.

Authors:  G A Higgins; G J Kilpatrick; K T Bunce; B J Jones; M B Tyers
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

8.  Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

Authors:  D Cunningham; J Hawthorn; A Pople; J C Gazet; H T Ford; T Challoner; R C Coombes
Journal:  Lancet       Date:  1987-06-27       Impact factor: 79.321

9.  Serotonergic status in human blood.

Authors:  J Ortiz; F Artigas; E Gelpí
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

10.  Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.

Authors:  M G Kris; R J Gralla; R A Clark; L B Tyson
Journal:  J Natl Cancer Inst       Date:  1989-01-04       Impact factor: 13.506
View more
  12 in total

1.  Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine.

Authors:  C P Bearcroft; P Domizio; F H Mourad; E A André; M J Farthing
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 2.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 3.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 4.  Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.

Authors:  G L Plosker; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

5.  The relationship between perioperative nausea and vomiting and serum serotonin concentrations in patients undergoing cesarean section under epidural anesthesia.

Authors:  Byung Gun Lim; Sang-Sik Choi; Yu Jin Jeong; Young Jin Lim; Yong Chul Kim; Kyoung Un Park; Dong Kyu Lee; Mi Kyoung Lee
Journal:  Korean J Anesthesiol       Date:  2014-12-29

6.  Cisplatin increases the release of 5-hydroxytryptamine (5-HT) from the isolated vascularly perfused small intestine of the guinea-pig: involvement of 5-HT3 receptors.

Authors:  H Schwörer; K Racké; H Kilbinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

7.  Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study.

Authors:  C P Bearcroft; D Perrett; M J Farthing
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

8.  Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.

Authors:  C P Schröder; W T van der Graaf; I P Kema; A Groenewegen; D T Sleijfer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.

Authors:  C R Lee; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

10.  In vitro release and tissue levels of ileal serotonin after cisplatin-induced emesis in the cat.

Authors:  S Milano; C Simon; L Grélot
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.